Objective. Proprotein convertase subtilisin kexin type 9 (PCSK9) is an important regulator of hepatic low-density lipoprotein (LDL)-cholesterol levels. Although PCSK9 is mainly of hepatic origin, extra-hepatic tissues significantly contribute to PCSK9 production and, potentially, local regulation of LDL receptor expression. Methods and results. In the present study we show that PCSK9 is expressed in smooth muscle cells (SMCs) and fibroblasts, but not in endothelial cells, macrophages and monocytes. PCSK9 was also detectable in human atherosclerotic plaques. Conditioned media from SMC affected LDLR expression and cholesterol uptake from -VLDL in the macrophage cell line J774. Co-cultured experiments also demonstrated the influence of SMCs on LDLR expression in J774. By retroviral overexpression or knockdown with small interfering RNA, we demonstrated that PCSK9 released from SMCs directly regulated LDLR expression in J774. Conclusions. Taken together our data indicate that PCSK9 secreted by human aortic SMCs is functionally active and capable to reduce LDLR expression in macrophages suggesting a possible direct role for this protein in atherogenesis.
|Titolo:||Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels|
|Data di pubblicazione:||3-nov-2011|
|Parole Chiave:||PCSK9 ; atherosclerosis ; smooth muscle cells ; macrophages|
|Settore Scientifico Disciplinare:||Settore BIO/14 - Farmacologia|
|Enti collegati al convegno:||Società Italiana di Farmacologia|
|Citazione:||Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels / N. Ferri, G. Tibolla, A. Pirillo, F. Cipollone, A. Mezzetti, S. Pacia, A. Corsini, A.L. Catapano. ((Intervento presentato al 5. convegno congresso monotematico della Società Italiana di Farmacologia ATEROTROMBOSI: DALLA RICERCA DI BASE ALLA CLINICA tenutosi a Milano nel 2011.|
|Appare nelle tipologie:||14 - Intervento a convegno non pubblicato|